Selecta Biosciences Stock Price and Value Analysis

Selecta Biosciences (NasdaqGM:SELB) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Selecta Biosciences to reach your target.

Target type

SELB Free Cash Flow Trend

Free Cash Flow trendline for SELB
Free Cash Flow trendline for Selecta Biosciences

Hmm, we can't give any reliable projection for Selecta Biosciences's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the SELB Numbers

SELB Price
(Selecta Biosciences stock price per share)
$0.00
[?] PE Ratio versus Sector 75% lower than other Healthcare stocks
[?] PE Ratio versus Industry 91% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 74%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 1 fiscal years from 2014 to 2025 with positive net income, operating cash flow totaled -$31.6 million against net income of $35.4 million, or -0.89 times. Net income was negative in 11 of the 12 years, and those years are left out of the ratio.

In 2025, net income was -$130 million and operating cash flow was -$73.9 million, so no ratio is shown for that year.

In 2020, capital expenditures were $0.8 million, 2.3% of operating cash flow of $34.9 million, which leaves an estimated $34.1 million after capex. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2014 -12.9 -12.7 0.2 n/a
2015 -25.2 -22.5 1.2 n/a
2016 -36.2 -19.7 0.6 n/a
2017 -65.3 -52 0.7 n/a
2018 -65.3 -59.2 0.9 n/a
2019 -55.4 -51.4 0 n/a
2020 -68.9 34.9 0.8 n/a
2021 -25.7 -60.4 1.1 n/a
2022 35.4 -31.6 1.2 -0.89
2023 -220 -51.2 0.2 n/a
2024 -77.4 -23.7 9.1 n/a
2025 -130 -73.9 5.5 n/a

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $3 million in 2014 and $2.8 million in 2025, a compound annual growth rate of -0.8% over 11 years.

Revenue fell 92.8% from 2024 to 2025.

Our estimated free cash flow was -$77.3 million in 2025, a negative margin of 2765.4% of revenue, meaning the estimate was below zero. In 2014 the estimated margin was negative 424.8%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2014 3 -12.9 -424.8%
2015 6 -23.2 -385.3%
2016 8.1 -20.3 -251.7%
2017 0.2 -52.7 -25460.5%
2018 0.9 -59.9 -6631.2%
2019 6.7 -52.1 -780.6%
2020 16.6 34.3 206.5%
2021 85.1 -61.1 -71.8%
2022 111 -32.4 -29.3%
2023 26 -51.8 -199.3%
2024 38.9 -26.2 -67.2%
2025 2.8 -77.3 -2765.4%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $125 million against total liabilities of $423 million, or 29.6% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 142.6% of total assets in 2025, compared with 372.0% in 2015, a decrease of 229.4 percentage points.

Stockholders equity was negative in 2025, at -$126 million, which means the company's liabilities and other claims on its assets exceeded the assets themselves. Companies that return cash through large buybacks can show negative equity for that reason alone, but it also leaves no book value cushion for shareholders.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -49.5% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2015 42.8 32.3 159 -116
2016 89.3 58.7 34.3 55
2018 44.5 37.4 49.9 -5.4
2019 99.6 89.9 91.2 8.4
2020 165 139 183 -18
2021 160 114 137 22.5
2022 166 106 72.1 93.8
2023 305 76.9 745 -440
2024 435 213 442 -6.8
2025 296 125 423 -126

Price Versus Our Estimated Value

Of the 12 fiscal years we can see for Selecta Biosciences under its current filer, 1 show positive free cash flow.

Free cash flow is volatile from year to year, with a variability measure of 74%.

We do not estimate a fair value for Selecta Biosciences while its free cash flow growth is not positive, so there is no value comparison here.

Dividends are not in our data for Selecta Biosciences.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 75% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 91% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Selecta Biosciences, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Selecta Biosciences (SELB) - - - - -
Abbott Laboratories (ABT) 178,390 38.4 2.4% 1.9% 49% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Amphastar Pharmaceuticals (AMPH) 1,205 13.0 - 0.9% 98% above
ANI Pharmaceuticals (ANIP) 1,558 13.9 - - 188% above
Bristol-Myers Squibb Company (BMY) 120,192 13.0 4.3% 1.2% 85% above
Collegium Pharmaceutical (COLL) 768 22.7 - - 155% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1453687.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 11 of the 12 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: SELB annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in SELB

Does Selecta Biosciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: SELB

This example shows how we apply the Trendshare checklist to SELB: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 0.00
    • Market cap: —
    • EPS: —
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.